Where does Credo Biomedical PTE Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Credo Biomedical PTE Ltd. ranks #39,661 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Credo Biomedical PTE Ltd. hold?

Credo Biomedical PTE Ltd. holds 6 US utility patents granted between 2017 and 2020, spanning 7 technology areas.

What is Credo Biomedical PTE Ltd.'s Innovation Score?

Credo Biomedical PTE Ltd. has an Innovation Score of 31.1 out of 100 (36th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Credo Biomedical PTE Ltd.'s patent grant rate increasing or decreasing?

Credo Biomedical PTE Ltd.'s recent grant velocity is -80% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Credo Biomedical PTE Ltd.'s patents?

Credo Biomedical PTE Ltd.'s patents average 31.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Credo Biomedical PTE Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Credo Biomedical PTE Ltd.

Q: What technology areas does Credo Biomedical PTE Ltd. focus on?

Credo Biomedical PTE Ltd.'s top technology area is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes) with 4 patents. Grants appear in 7 CPC subclasses total.

USPTO PatentsView assignee record - 6 granted patents across 7 technology areas, recorded in grant years 2017–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Credo ranks #39,661 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 7 technology areas.

#39,661
of 49,997 US assignees by volume: 36th percentile
by Innovation Score (31.1/100): 31.7
avg claims per patent: -80%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R39661 · Foreign Corporation #39,661 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 6 grants
LOWER-Q #39,661/49,997
PHOTO-FINISH CPT Zwei
CPC-NARROW C12Q · 7 areas
INNOV-THIN 31.1/100
CLAIMS-DENSE 31.7 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -80% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: CPT Zwei GmbH (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Credo Biomedical PTE · this assignee

31
3D Lighting… · lowest

7

What this shows Credo's Innovation Score is 31.1/100 (36th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Credo's grants concentrate

Credo Biomedical PTE Ltd. is a focused PatentsView assignee: 7 CPC subclasses with 66.7% of grants classified under C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr). Peak complete grant year is 2019 (3 grants) versus a trough of 1 in 2017. By volume, Credo sits between CPT Zwei GmbH and Crocodile Products Inc..

CPT Zwei

6
Crane Payment Sol…

6
CRC Care PTY

6
Creaform

6
Cresyn

6
Cretem

6
CRF BOX OY

6
Crocodile Products

6
Credo Biomedical… ◀

6

What this shows Credo holds 6 patents at rank #39,451, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Credo

By rank, the assignees closest to #39,451 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Credo's primary technology class.

Credo's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

31 36th percentile higher than 36% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Credo Biomedical PTE Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	16.7%
2018	1	16.7%
2019	3	50.0%
2020	1	16.7%

Which technologies does Credo Biomedical PTE Ltd. patent most?

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 4

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

B01L - Chemical OR Physical Laboratory Apparatus FOR General USE 2

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 2

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 1

B01F - Mixing, e.g. Dissolving, Emulsifying OR Dispersing 1

B01D - Separation 1

Top 7 of 7 technology areas

Where it ranks

Overall rank by patents

#39,661

of 49,997 tracked assignees

Innovation Score

31.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Credo Biomedical PTE Ltd.'s patent record in context - here's where to go next.

Credo Biomedical PTE Ltd.'s lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 66.7% of its portfolio - see every assignee active in that class. Explore C12Q
Ranked #39,661 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Credo Biomedical PTE Ltd. against CPT Zwei GmbH, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 31.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.